Endometriosis-associated infertility: evaluation of preoperative use of danazol, gestrinone, and buserelin.

Jacques Donnez, J Donnez, M Nisolle-Pochet, F Casanas-Roux, F. Casanas‐Roux
International journal of fertility · 1991 · vol. 35(5) , pp. 297–301 · PMID:1980666 · W1799475644
article OA: closed CC0 ⤵ 20 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Buserelin showed superior regression of ovarian endometriosis compared to danazol or gestrinone, but hormonal therapy alone incompletely suppressed implants, necessitating surgical removal.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In order to assess adequately the effectiveness of danazol, Gestrinone, and Buserelin, a prospective nonrandomized study was initiated in 126 patients with laparoscopically confirmed ovarian endometriosis. After hormonal therapy, laparotomy with microsurgical resection of endometriotic cysts was carried out. Regression (greater than 25%) of ovarian endometriosis was noted in 30%, 34%, and 73% of cases after danazol, Gestrinone, and Buserelin, respectively. The pregnancy rate in moderate endometriosis (53%) differed significantly from the rate obtained in severe endometriosis (45%). The highest percentages were found after Buserelin therapy. In conclusion, Buserelin emerged superior to danazol or Gestrinone treatment. Nevertheless, hormonal treatment leads to an incomplete suppression of ovarian endometriotic implants and this suggests the necessity of surgically removing invasive ovarian endometriosis.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisinfertility

MeSH descriptors

Buserelin Danazol Endometriosis Gestrinone Infertility, Female Ovarian Neoplasms Adult Buserelin Combined Modality Therapy Danazol Endometriosis Endometriosis Endometriosis Female Gestrinone Humans Infertility, Female Infertility, Female Ovarian Neoplasms Ovarian Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (20)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:05.481982+00:00
License: CC0 · commercial use OK